Methods A retrospective review of all lung cancer patients with a multidisciplinary team
outcome of BSC from 01 June 2018 to 01 June 2019 was performed. Patients were …

The UK has been highlighted, by the International Cancer Benchmarking Project and the
EUROCARE groups, as a country with one of the lowest lung cancer survival rates. It has …

Individuals from five thoracic oncology centers in the United States recently met to discuss
how to integrate molecular profiling into the care of all patients with carcinoma of the lung …

Background Most patients with lung cancer are diagnosed at advanced stages. However,
the advent of oral targeted therapies has improved the prognosis of many patients with lung …

Background The optimal diagnostic and staging strategy for patients with suspected lung
cancer is not known. Research Question What diagnostic and staging strategies are most …

The discovery of diverse driver mutations in lung cancer has heralded a new era of
personalized medicine in thoracic oncology, with targeted therapies approved for specific …

Background: Histologic and molecular subtyping have become increasingly important as
predictors of treatment benefit in lung cancer. The objective of the present study was to …

In the absence of screening, most patients with lung cancer are not diagnosed until later
stages, when the prognosis is poor. The most common symptoms are cough and dyspnea …

Purpose Lung cancer is the leading cause of cancer death in Australia, but little is known
about how Australian patients with this disease are managed. Methods Lung cancer patients …

Background This guideline is intended to provide an evidence-based approach to the initial
evaluation of patients with known or suspected lung cancer. It also includes an assessment …